Last reviewed · How we verify
MVA-FCU1, flucytosine
MVA-FCU1, flucytosine is a Biologic drug developed by Transgene. It is currently in Phase 1 development. Also known as: 5-FC.
At a glance
| Generic name | MVA-FCU1, flucytosine |
|---|---|
| Also known as | 5-FC |
| Sponsor | Transgene |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MVA-FCU1, flucytosine CI brief — competitive landscape report
- MVA-FCU1, flucytosine updates RSS · CI watch RSS
- Transgene portfolio CI
Frequently asked questions about MVA-FCU1, flucytosine
What is MVA-FCU1, flucytosine?
MVA-FCU1, flucytosine is a Biologic drug developed by Transgene.
Who makes MVA-FCU1, flucytosine?
MVA-FCU1, flucytosine is developed by Transgene (see full Transgene pipeline at /company/transgene).
Is MVA-FCU1, flucytosine also known as anything else?
MVA-FCU1, flucytosine is also known as 5-FC.
What development phase is MVA-FCU1, flucytosine in?
MVA-FCU1, flucytosine is in Phase 1.
Related
- Manufacturer: Transgene — full pipeline
- Also known as: 5-FC
- Compare: MVA-FCU1, flucytosine vs similar drugs
- Pricing: MVA-FCU1, flucytosine cost, discount & access